PubRank

Y Urasaki

Author PubWeight™ 15.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001 2.04
2 Organization of the replication control region of plasmid ColIb-P9. J Bacteriol 1990 1.12
3 Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 2001 1.06
4 Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 2000 1.06
5 Enlargement of mandibular canal without hypesthesia caused by extranodal non-Hodgkin's lymphoma: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000 1.02
6 Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7. Oncogene 2006 0.96
7 Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001 0.88
8 Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicin. Oncol Res 1996 0.83
9 CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 2009 0.82
10 Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998 0.82
11 Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 2001 0.81
12 Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 1994 0.79
13 Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin. Leuk Res 1998 0.77
14 Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug-resistant K562 cells. Leuk Res 2000 0.77
15 Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome. Anticancer Res 1995 0.76
16 Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. Jpn J Cancer Res 2001 0.76
17 Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells. Leuk Res 1999 0.76
18 Successful treatment of cytomegalovirus retinitis in a patient with malignant lymphoma: a case report and review of the literature. Int J Hematol 1999 0.75
19 Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res 2001 0.75
20 Excretion of indomethacin into saliva following intravenous administration to dogs. J Pharmacobiodyn 1981 0.75
21 Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute. J Infect Chemother 2001 0.75
22 Protein binding effects of salivary excretion of phenobarbital in dogs. J Pharmacobiodyn 1981 0.75
23 Influence of idarubicinol on the antileukemic effect of idarubicin. Leuk Res 1994 0.75
24 Successful treatment of acquired myelofibrosis with pure red cell aplasia by cyclosporine. Br J Haematol 1999 0.75
25 [Treatment of acute lymphoblastic leukemia in adults: a review of 10 year study of Japan Adult Leukemia Study Group]. Rinsho Ketsueki 1997 0.75
26 Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line. Anticancer Res 2000 0.75
27 [Prosthetic replacement of arthritis joints: management of the prosthesis and prevention of postoperative fractures and dislocations]. Kango Gijutsu 1988 0.75